房颤患者减剂量NOAC的疗效与安全性:随机对照试验荟萃分析
该荟萃分析汇总比较NOAC与华法林的III期随机对照试验数据,按患者是否符合NOAC减量条件分层。结果显示,符合减量条件者卒中或系统性栓塞及大出血年化发生率均更高;减剂量NOAC相比华法林在卒中或系统性栓塞及大出血方面的效应与全剂量NOAC相比华法林一致,且无论是否符合减量条件,NOAC均降低出血性卒中、颅内出血、致命性出血和死亡风险。
要点
- 符合NOAC减量条件者血栓栓塞及出血并发症风险更高。
- 减剂量NOAC相比华法林的获益-风险特征与全剂量NOAC一致。
- 无论是否符合减量条件,NOAC均降低颅内出血和死亡风险。
核心结论
- 符合减剂量NOAC条件的房颤患者在接受抗凝治疗时血栓栓塞和出血并发症风险升高。
- NOAC适当调整剂量后相比华法林具有更优的获益-风险特征。
- 研究结果强调对符合指征的人群处方减剂量NOAC的重要性。
研究设计与样本
- 荟萃分析,汇总比较NOAC与华法林的III期随机对照试验数据。
- 按患者是否符合NOAC减量条件进行分层,采用风险比(RR)和95%置信区间(CI)评估治疗效应。
主要发现
- 无论治疗如何,符合减量条件者卒中或系统性栓塞年化发生率为2.70%,高于符合全剂量条件者的1.60%。
- 无论治疗如何,符合减量条件者大出血年化发生率为4.35%,高于符合全剂量条件者的2.87%。
- 符合减量条件者中,减剂量NOAC相比华法林对卒中或系统性栓塞的RR为0.84(95% CI 0.69-1.03)。
- 符合减量条件者中,减剂量NOAC相比华法林对大出血的RR为0.70(95% CI 0.50-0.97)。
- 符合全剂量条件者中,全剂量NOAC相比华法林对卒中或系统性栓塞的RR为0.86(95% CI 0.77-0.96),对大出血的RR为0.87(95% CI 0.70-1.08)。
关键数值与推荐
- 减剂量NOAC相比华法林与全剂量NOAC相比华法林在卒中或系统性栓塞上的交互作用P=0.89。
- 减剂量NOAC相比华法林与全剂量NOAC相比华法林在大出血上的交互作用P=0.26。
- 无论是否符合NOAC减量条件,NOAC降低出血性卒中、颅内出血、致命性出血和死亡风险,交互作用P均>0.05。
临床怎么用
- 对符合减量条件的房颤患者应按指征处方减剂量NOAC,不应随意减量或全剂量使用。
- 减剂量NOAC相比华法林仍具有更优的获益-风险特征,可用于符合减量条件的高危患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Non-vitamin K antagonist oral anticoagulants (NOACs) require dose reductions according to patient or clinical factors for patients with atrial fibrillation (AF). In this meta-analysis, we aimed to assess outcomes with reduced-dose NOACs when given as pre-specified in pivotal trials. METHODS AND RESULTS: Aggregated data abstracted from Phase III trials comparing NOACs with warfarin in patients with AF were assessed by treatment using risk ratios (RRs) and 95% confidence intervals (CIs) stratified by patient eligibility for NOAC dose reduction. Irrespective of treatments, annualized rates of stroke or systemic embolism and major bleeding were higher in patients eligible for reduced-dose NOACs than in those eligible for full-dose NOACs (2.70% vs. 1.60% and 4.35% vs. 2.87%, respectively). Effects of reduced-dose NOACs compared with warfarin in patients eligible for reduced-dose NOACs on stroke or systemic embolism [RR 0.84 (95% CI 0.69-1.03)] and on major bleeding [RR 0.70 (95% CI 0.50-0.97)] were consistent with those of full-dose NOACs relative to warfarin in those eligible for full-dose NOACs [RR 0.86 (95% CI 0.77-0.96) for stroke or systemic embolism and RR 0.87 (95% CI 0.70-1.08) for major bleeding; interaction P, 0.89 and 0.26, respectively]. In addition, NOACs were associated with reduced risks of haemorrhagic stroke, intracranial haemorrhage, fatal bleeding, and death regardless of patient eligibility for NOAC dose reduction (interaction P > 0.05 for each). CONCLUSIONS: Patients eligible for reduced-dose NOACs were at elevated risk of thromboembolic and haemorrhagic complications when treated with anticoagulants. NOACs, when appropriately dose-adjusted, had an improved benefit-harm profile compared with warfarin. Our findings highlight the importance of prescribing reduced-dose NOACs for indicated patient populations.
引用
- Wang KL, Lopes RD, Patel MR, et al. Efficacy and safety of reduced-dose non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: a meta-analysis of randomized controlled trials. Eur Heart J. 2019. PMID: 30590440. doi:10.1093/eurheartj/ehy802
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。